MMRF 25 Voices - George Mulligan

20 years ago, MMRF Chief Scientific Officer George Mulligan was working as a translational researcher on a clinical trial for a drug candidate called “PS 341”. The hospitals whose patients were enrolled in the trial would share samples with George’s team. The data showed positive results in multiple myeloma patients that they had never seen before. That drug turned out to be Velcade and it was the beginning of a revolution in myeloma therapy. To this day, Dr. Mulligan feels a connection to the patients on that trial and it inspires his work at the MMRF to continue to make extraordinary things happen for the myeloma community. #25Voices #MMRF25

[@pleaaselouise]

Thank you. I am a new patient player. I am 76, so I don’t think I will get the benefits of the new treatments.